In the intricate world of endocrine science, understanding the difference between the physiologic effects of naturally occurring hormones and the pharmacologic effects induced by medication is crucial.

"Physiologic" pertains to what naturally happens in the body. Eating different foods, for instance, can naturally modulate hormone levels like GLP1, which is integral in appetite control.

On the other end of the spectrum is the pharmacologic effect. This arises from using drugs that vastly increase the concentration of specific hormones in the blood, such as GLP1 agonists, which are 3,000 to 10,000 times more concentrated than natural levels.

There’s no precedent in diet leading to such vast concentration changes; only pharmacologic interventions can achieve this.

The pharmaceutical spotlight currently shines on GLP1 agonists, known for their comprehensive health benefits. Originally used for diabetes, emerging research suggests their potential in reducing alcohol cravings and surprising heart health benefits.

Despite the scrutiny over their use due to super physiological dosages, research has nourished a landscape of benefits stemming from GLP1 agonists. Some of the early drugs have been around since 2005 and passed rigorous cardiac safety trials demonstrating reduction in heart disease-related deaths, independent of significant weight reduction.

Advancements are accelerating in the realm of GLP1 multi-agonists. Notable developments include medications combining GLP1 with others like GIP and glucagon for improved physiologic effects without side effects such as nausea.

Eli Lilly’s invention of a triple agonist, inclusive of glucagon to enhance energy expenditure, heralds impressive weight loss figures which rival contemporary bariatric surgery.

Amgen’s new approach incorporates antibody technology, demi φ laborating long-lasting hormone interaction possibilities that can ensure weight stability even after treatment cessations.

What started as a restrictive field due to past medical errors in old drug efforts, has turned into a Minnesota explosion of innovation in obesity treatment drugs. GLP1's diversifying applicability has rejuvenated pharmaceutical interest, enthusing a renaissance in obesity drug discovery, driven by safety and efficacy like never before.